Chimeric antigen receptor T cell (CAR-T) immunotherapy for solid tumors: lessons learned and strategies for moving forward

Recently, the US Food and Drug Administration (FDA) approved the first chimeric antigen receptor T cell (CAR-T) therapy for the treatment CD19-positive B cell acute lymphoblastic leukemia. While CAR-T has achieved remarkable success in the treatment of hematopoietic malignancies, whether it can bene...

Descripción completa

Detalles Bibliográficos
Autores principales: Li, Jian, Li, Wenwen, Huang, Kejia, Zhang, Yang, Kupfer, Gary, Zhao, Qi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2018
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5809840/
https://www.ncbi.nlm.nih.gov/pubmed/29433552
http://dx.doi.org/10.1186/s13045-018-0568-6

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5809840/
https://www.ncbi.nlm.nih.gov/pubmed/29433552
http://dx.doi.org/10.1186/s13045-018-0568-6

Ejemplares similares